Drug Trial Radar · NCT03866174
A Study of Psilocybin for Major Depressive Disorder (MDD)
Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
347
Actual
Start
Jan 23, 2020
Primary completion
Jun 28, 2022
Study completion Jun 28, 2022
Sponsor
- Lead sponsor
- Usona InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Emmes Company, LLC
- First posted
- Mar 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
One hundred participants, ages 21 to 65, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for major depressive disorder (MDD) will be stratified by study site and randomized with a 1-to-1 allocation under double-blind conditions to receive a single 25 mg oral dose of psilocybin or a single 100 mg oral dose of niacin. Niacin will serve as an active placebo. The purpose of this study is to evaluate the potential efficacy of a single 25 mg oral dose of psilocybin for MDD compared to the active placebo in otherwise medically-healthy participants, assessed as the difference between groups in changes in depressive symptoms from Baseline to Day 43 post-dose.
Conditions
- Depressive Disorder, Major
Interventions
PsilocybinDrug
The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.
NiacinDrug
The active placebo is encapsulated using a HPMC capsule and contains 100 mg of pharmaceutical grade niacin.
Set and Setting (SaS) ProtocolOther
The SaS Protocol prescribes 6-8 hours of preparatory meetings with two facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two facilitators, and 4 hours of post-dose integration sessions with facilitators. During the dosing session participants are encouraged to wear eyeshades and listen to a curated playlist on headphones.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Central Rater Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Post-dose Day 43Time frame: Baseline; Day 43 post-dose
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California
Pacific Neuroscience Institute
Santa Monica, California
Yale University
New Haven, Connecticut
Segal Trials
Lauderhill, Florida
Emory University
Atlanta, Georgia
Great Lakes Clinical Trials
Chicago, Illinois
Johns Hopkins University
Baltimore, Maryland
Hassman Research Institute
Berlin, New Jersey
New York University School of Medicine
New York, New York
Cedar Clinical Research
Draper, Utah
University of Wisconsin - Madison
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.